Effects of guanabenz therapy on renal function and body fluid composition.
Guanabenz acetate is a new centrally acting alpha 2-adrenergic agonist. Seventeen hypertensive men, in whom BP was normalized with guanabenz, underwent assessment of renal function, renal hemodynamics, and body fluid composition following short-term (three to six weeks), long-term (five to six months), and withdrawal (two weeks) therapy. Guanabenz therapy caused a modest but reversible reduction in glomerular filtration rate (12% to 18%), effective renal plasma flow (9% to 17%), and renal blood flow (12% to 20%). Renal vascular resistance was unchanged. Guanabenz therapy had no significant natriuretic or antinatriuretic effects in patients with an effective BP decrease, although it had the ability to produce and sustain a water diuresis. Guanabenz therapy was not associated with salt and water increases within body fluid compartments. Guanabenz, in some patients, is an effective monotherapy for the treatment of hypertension.
D001794:Blood Pressure / Q000187:drug effects; D001795:Blood Pressure Determination; D001826:Body Fluids / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D005919:Glomerular Filtration Rate; D006143:Guanabenz / Q000494:pharmacology / Q000627:therapeutic use*; D006146:Guanidines / Q000627:therapeutic use*; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D007668:Kidney / Q000098:blood supply / Q000187:drug effects* / Q000502:physiology; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011674:Pulse / Q000187:drug effects; D014655:Vascular Resistance / Q000187:drug effects
D006146:Guanidines; D006143:Guanabenz